{"id":1111,"date":"2001-01-01T12:03:00","date_gmt":"2001-01-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/lipidsenker-reduzieren-koronare-ereignisse-bei-patienten-mit-hyperlipidaemie-auch-in-der-primaerpraevention"},"modified":"2001-01-01T12:03:00","modified_gmt":"2001-01-01T11:03:00","slug":"lipidsenker-reduzieren-koronare-ereignisse-bei-patienten-mit-hyperlipidaemie-auch-in-der-primaerpraevention","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/lipidsenker-reduzieren-koronare-ereignisse-bei-patienten-mit-hyperlipidaemie-auch-in-der-primaerpraevention","title":{"rendered":"Lipidsenker reduzieren koronare Ereignisse bei Patienten mit Hyperlipid\u00e4mie auch in der Prim\u00e4rpr\u00e4vention"},"content":{"rendered":"<p>Hersteller von Pharmaka haben bei der Food and Drug Administration (FDA) der USA k\u00fcrzlich beantragt, da\u00df Statine auch rezeptfrei (&#8222;Over the counter&#8220;) verkauft werden d\u00fcrfen. Begr\u00fcndung: Bei Patienten mit erh\u00f6htem koronaren Risiko w\u00fcrden diese Medikamente von \u00c4rzten zu selten verschrieben. Die FDA hat diesen Antrag abgelehnt, insbesondere wegen unzureichender Kenntnisse \u00fcber die Langzeit-Sicherheit der Statine. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hersteller von Pharmaka haben bei der Food and Drug Administration (FDA) der USA k\u00fcrzlich beantragt, da\u00df Statine auch rezeptfrei (&#8222;Over the counter&#8220;) verkauft werden d\u00fcrfen. Begr\u00fcndung: Bei Patienten mit erh\u00f6htem koronaren Risiko w\u00fcrden diese Medikamente von \u00c4rzten zu selten verschrieben. Die FDA hat diesen Antrag abgelehnt, insbesondere wegen unzureichender Kenntnisse \u00fcber die Langzeit-Sicherheit der Statine. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[495,451,452,448,449,2780,455,453,498,456,454,801,443],"class_list":["post-1111","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angina-pectoris","tag-cholesterinsynthese-hemmer","tag-cholestyramin","tag-colestyramin","tag-cse-hemmer","tag-gemfibrocil","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-lovastatin","tag-pravastatin","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1111"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1111\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}